The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

BACKGROUND: Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Werutsky, Gustavo, Maluf, Fernando Cotait, Cronemberger, Eduardo Henrique, Carrera Souza, Vinicius, dos Santos Martins, Suelen Patricia, Peixoto, Fábio, Smaletz, Oren, Schutz, Fábio, Herchenhorn, Daniel, Santos, Telma, Mavignier Carcano, Flavio, Queiroz Muniz, David, Nunes Filho, Paulo R. S., Zaffaroni, Facundo, Barrios, Carlos, Fay, André
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6533731/
https://ncbi.nlm.nih.gov/pubmed/31122212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5709-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados